Compare Stocks → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AZRXNASDAQ:FBRXNASDAQ:IMRNNASDAQ:KZIANASDAQ:OHRP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAZRXAzurRx BioPharma$3.12+7.2%$4.04$3.36▼$26.30$29.10M1.51628,703 shs151,007 shsFBRXForte Biosciences$0.71-4.1%$0.70$0.38▼$1.15$26.88M0.4826,555 shs14,300 shsIMRNImmuron$2.49+1.2%$5.04$1.92▼$28.99$14.02M1.4322,166 shs1,273 shsKZIAKazia Therapeutics$0.39-2.5%$0.30$0.19▼$1.43$6.45M2.12406,784 shs103,928 shsOHRPOHR Pharmaceutical$0.42$7.37$1.60▼$6.28$1.19M0.84180,228 shs21,218 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAZRXAzurRx BioPharma0.00%+7.59%-24.27%-23.72%+12.43%FBRXForte Biosciences-3.87%-4.05%0.00%+3.59%-32.38%IMRNImmuron-1.58%+3.32%-4.60%+34.59%+16.90%KZIAKazia Therapeutics-1.52%+13.38%+45.15%+5.28%-70.66%OHRPOHR Pharmaceutical0.00%+0.26%-57.90%-30.07%+197.53%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AFBRXForte Biosciences3.2914 of 5 stars3.35.00.00.02.22.51.3IMRNImmuronN/AN/AN/AN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAZRXAzurRx BioPharmaN/AN/AN/AN/AFBRXForte Biosciences2.50Moderate Buy$2.75287.32% UpsideIMRNImmuronN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/ACurrent Analyst RatingsLatest AZRX, FBRX, OHRP, KZIA, and IMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2024FBRXForte BiosciencesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.75(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$0.97 per shareN/AIMRNImmuron$1.22M11.63N/AN/A$2.32 per share1.07KZIAKazia Therapeutics$20K317.81N/AN/A$0.50 per share0.78OHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/AFBRXForte Biosciences-$31.48M-$1.04N/AN/AN/AN/A-94.27%-81.36%5/20/2024 (Estimated)IMRNImmuron-$2.55MN/A0.00∞N/AN/AN/AN/AN/AKZIAKazia Therapeutics-$13.78MN/A0.00N/AN/AN/AN/AN/AN/AOHRPOHR Pharmaceutical-$13.23MN/A0.00∞N/AN/A-75.46%-71.18%N/ALatest AZRX, FBRX, OHRP, KZIA, and IMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023FBRXForte BiosciencesN/A-$0.04-$0.04-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAZRXAzurRx BioPharmaN/A1.331.33FBRXForte BiosciencesN/A10.4510.45IMRNImmuronN/A8.527.79KZIAKazia TherapeuticsN/A0.71N/AOHRPOHR PharmaceuticalN/A3.733.73OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAZRXAzurRx BioPharma6.27%FBRXForte Biosciences77.63%IMRNImmuron0.12%KZIAKazia Therapeutics30.89%OHRPOHR Pharmaceutical10.70%Insider OwnershipCompanyInsider OwnershipAZRXAzurRx BioPharma7.30%FBRXForte Biosciences10.53%IMRNImmuron7.01%KZIAKazia Therapeutics1.00%OHRPOHR Pharmaceutical12.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableFBRXForte Biosciences936.40 million32.56 millionOptionableIMRNImmuronN/A5.70 million5.30 millionNot OptionableKZIAKazia Therapeutics2,02116.34 million16.18 millionOptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionableAZRX, FBRX, OHRP, KZIA, and IMRN HeadlinesSourceHeadlinePharmaceutical Stocksbenzinga.com - April 14 at 8:00 AMCYCC Cyclacel Pharmaceuticals, Inc.seekingalpha.com - March 17 at 4:20 PMSun Pharmaceutical Industries Ltd.moneycontrol.com - February 3 at 8:52 AMAI Advances Pharmaceutical Packaging Inspectiondesignnews.com - May 22 at 9:22 AMThe OHRP and SUPPORT — Another Viewnejm.org - April 21 at 3:16 PMWorking at the Smithsoniansi.edu - February 23 at 5:49 PMOHR Pharmaceutical (OHRP) is now in Oversold Territoryca.finance.yahoo.com - September 12 at 11:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAzurRx BioPharmaNASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.Forte BiosciencesNASDAQ:FBRXForte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.ImmuronNASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Kazia TherapeuticsNASDAQ:KZIAKazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.OHR PharmaceuticalNASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.